Biodexa Pharmaceuticals plc American Depositary Shs (BDRX)
NASDAQ: BDRXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
Market open · Delayed 15 min · as of Oct 9, 10:16 AM ET
BDRX stock chart
Technical analysisKey statistics
All statistics- Market cap
- $1.08M
- P/E (TTM)
- 0.01
- EPS (TTM)
- $63.74
- Dividend yield
- None
- 52-week range
- 0.473 – 52.05
- Day range
- 0.473 – 0.52
- Volume / Avg
- 55.26K / 3.72M
- Beta
- —
- Shares outstanding
- 2.20M
52-week range
BDRX stock today
Shares of Biodexa Pharmaceuticals American Depositary Shs (BDRX) are trading lower on Oct 9 at $0.4914, a drop of 6.17% or $0.0323 per share, versus the S&P 500's 0.33% gain. At this level, BDRX sits near the bottom of its 52-week range of $0.473 to $52.05: 99.1% below the high and 3.9% above the low. Biodexa Pharmaceuticals American Depositary Shs trades at 0.0x its trailing twelve-month earnings per share of $63.74.
Summary generated from market data by MetaCap's automated system. Methodology
About Biodexa Pharmaceuticals American Depositary Shs
Company profileBiodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of familial adenomatous polyposis, non-muscle invasive bladder cancer, and Type 1 diabetes and rare/orphan brain cancer. Its lead product candidate, Tolimidone, is a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of recurrent glioblastoma, diffuse midline glioma, and medulloblastoma; and MTX240, for the treatment of gastrointestinal stromal tumors.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Stephen Anthony Stamp
- Headquarters
- Cardiff
- Employees
- 11
- Website
- biodexapharma.com
Analyst forecast
ForecastConsensus
none
Avg. price target
$8.91+1713.19%
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Biodexa Pharmaceuticals American Depositary Shs peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| SBFMSunshine Biopharma Inc. | 0.3785 | -11.98% | $1.63M | vs BDRX |
| ARTLArtelo Biosciences Inc. | 3.38 | +0.30% | $1.85M | vs BDRX |
| LABTLakewood-Amedex Biotherapeutics Inc. | 0.79 | -0.25% | $1.87M | vs BDRX |
| SXTCChina SXT Pharmaceuticals Inc. Class A | 0.1813 | -47.39% | $239.57K | vs BDRX |
| OGENOragenics Inc. | 0.463 | 0.00% | $2.09M | vs BDRX |
| MDCXMedicus Pharma Ltd. | 0.0922 | -9.45% | $138.22K | vs BDRX |
| CDTCDT Equity Inc. | 0.7199 | -10.01% | $29.18K | vs BDRX |
| PBMPsyence Biomedical Ltd. | 4.99 | -2.39% | — | vs BDRX |
Indexes, lists and sector
Biodexa Pharmaceuticals American Depositary Shs stock FAQ
What is Biodexa Pharmaceuticals American Depositary Shs's stock price today?
BDRX last traded at $0.4914 as of Oct 9, 10:16 AM EDT, down 6.17% on the day. Prices are delayed at least 15 minutes.
What is BDRX's P/E ratio?
BDRX trades at a trailing P/E ratio of 0.01.
Who is Biodexa Pharmaceuticals American Depositary Shs's CEO?
Mr. Stephen Anthony Stamp is the chief executive officer of Biodexa Pharmaceuticals plc American Depositary Shs, which has about 11 employees.
What is the BDRX 52-week high?
The 52-week high for BDRX is $52.05 and the 52-week low is $0.473. The stock is currently 99.1% below its high.